Skip to main content
. 2021 Dec 31;14(1):69. doi: 10.3390/v14010069

Figure 2.

Figure 2

Validation of the SARS-CoV-2, SARS-CoV, and MERS-CoV pseudoviruses and ACE2 and DPP4 expression in different cell lines. (a) Immunoblot to validate the incorporation of the spike (S) protein in the SARS-CoV and SARS-CoV-2 pseudoviruses (b) Immunoblot to validate the incorporation of the spike (S) protein in the MERS-CoV pseudovirus Infection of cells expressing different levels of angiotensin-converting enzyme 2 (ACE2) with (c) the same amounts of SARS-CoV-2 or (d) SARS-CoV pseudovirus. (e) Infection of cells expressing different levels of dipeptidyl peptidase 4 (DPP4), with the same amounts of MERS-CoV pseudovirus. Columns represent the means ± standard deviations (n = 4). (f) Immunoblot of cell lysates to evaluate ACE2 expression (Blot 1 and Blot 2) and DPP4 expression (Blot 3). β-Actin was used as a loading control.